Skip to main contentSkip to navigationSkip to search

CEO statement Q3 2026

Broad-based growth and strong earnings

Camurus had a record third quarter, with total revenues of SEK 724 million, up 28 percent, and an operating result of SEK 322 million, up 40 percent, with no milestone revenue in the period. Product sales reached an all-time high SEK 582 million on continued growth for Buvidal®, and Brixadi royalties increased 23 percent. During the quarter, the FDA accepted the resubmission of the NDA for CAM2029 for review in acromegaly and Oczyesa was approved in Australia. After the period, Oczyesa XR was approved in Canada, and Brixadi reached its first sales milestone. Based on performance to date, full-year revenues and operating result are expected in the upper half of the guided ranges.

Step up in both sales and profitability

The third quarter was our strongest to date. Total revenues increased 28 percent to SEK 724 million (25 percent at CER). Product sales reached a record SEK 582 million, representing growth of 28 percent year-on-year and 10 percent compared with the second quarter, while Brixadi royalties in the US increased 23 percent year-on-year to SEK 137 million. With no milestone revenue in the quarter, the increase reflects the underlying growth of the commercial business. The operating result increased 40 percent to SEK 322 million, corresponding to an operating margin of 44 percent. Cash flow from operating activities amounted to SEK 325 million, and the cash position increased to around SEK 4.4 billion at the end of the quarter.

For the first nine months, total revenues were SEK 1,959 million and the operating result SEK 783 million. The comparison with 2025 includes license revenues from Lilly in both periods: SEK 46 million during 2026 and SEK 115 million last year. Excluding these one-time revenues, revenues grew around 13 percent and the operating result grew approximately 14 percent. Overall, the third quarter marks continued progress in both sales and profitability.

Buvidal growth and continued patient expansion

Buvidal sales reached SEK 574 million in the quarter, an increase of 26 percent year-on-year. Underlying in-market sales increased 26 percent year-on-year and 5 percent sequentially, reflecting broad-based growth across our markets.

Performance was positive in the UK, the Nordics, Germany, France and Spain. UK growth was driven mainly by improved access in prisons, while work continues with stakeholders to trans-late recently allocated community funding into broader patient access. Progress in the community setting has been slower than expected, but the direction is positive.

Sales in the Nordics benefited from expanded access, continued switching from daily treatment and the transfer of remaining patients from another long-acting buprenorphine product. Germany continued to deliver further solid market penetration. In Australia, patient transfers from another long-acting treatment began toward the end of the quarter, with most patients expected to transfer by year-end.

For the first nine months, reported Buvidal sales increased approximately 8 percent (9 percent at CER), while in-market sales grew approximately 27 percent. The difference reflects inventory build at UK wholesalers in the first half of 2025, before the UK operating model was changed. At the end of the quarter, an estimated 81,000 patients were receiving Buvidal – around 4,000 more than at the end of the second quarter – keeping us on track toward our ambition of 100,000 patients at the end of 2027.

Brixadi* reaches first sales milestone on continued US growth

Brixadi continued to grow in the US during the quarter, with increased use across treatment settings. Royalty revenues from our license partner Braeburn increased 23 percent year-on-year (21 percent at CER) to SEK 137 million, and 8 percent compared with the previous quarter. For the first nine months, royalties increased 35 percent (36 percent at CER).

Braeburn further expanded its US commercial organization to drive Brixadi performance, and its medical organization to strengthen scientific exchange and clinical education with health-care providers. The growing adoption of long-acting injectable buprenorphine in the US reinforces the longer-term opportunity for Brixadi, the only long-acting injectable buprenorphine offering both weekly and monthly dosing, in this expanding market.

After the period, Brixadi net sales in 2026 exceeded USD 300 million, triggering the first USD 15 million sales milestone payment, to be recognized in the fourth quarter.

Oczyesa positive market response and continued launch progress

Oczyesa offers people with acromegaly a new treatment option designed to provide effective disease control, with the convenience of once-monthly self-administration using an autoinjector pen.

The sales of Oczyesa grew 83 percent compared with the previous quarter to SEK 8 million, with the majority coming from Germany, our initial launch market, with a limited contribution from Sweden following its launch in September. In Germany, the share of acromegaly patients treated with somatostatin receptor ligands who received Oczyesa increased to 5 percent, from 2.5 percent at the end of the second quarter. The response from healthcare professionals and patients remains generally very positive, supporting our ambition for strong and sustainable growth. The pace of uptake depends on how frequently patients visit their clinic, as these visits provide the opportunity to discuss and implement a change in treatment.

In the UK, where Oczyesa has been available since March, broader adoption depends on local formulary decisions, the first of which are expected in the fourth quarter.

In August, Oczyesa received marketing authorization in Australia. The launch timing will be decided in the context of a potential future indication in gastroenteropancreatic neuroendo-crine tumors (GEP-NET). After the period, Oczyesa XR received Notice of Compliance (i.e. regulatory approval) from Health Canada, and launch in Canada is planned for 2027.

CAM2029 regulatory update and SORENTO progress

The US FDA accepted the resubmission of the NDA for CAM2029 (Oclaiz**) in acromegaly in July, with a PDUFA target action date of 18 December, 2026. The review is progressing, and we are in dialogue with the FDA regarding the timing of a reinspection of the current third-party manufacturing site.

In parallel, we are preparing to add a secondary manufacturing site, based in the US, to the application. This site recently completed an FDA GMP inspection. Additionally, a Phase 1 study in 130 healthy volunteers has demonstrated bioequivalence between product from the current European and the new US manufacturer. The FDA has been informed about our plans to establish an alternative manufacturing site, and the information has been shared with the review team. The addition would constitute a major amendment, which could extend the review period by three months from the current PDUFA date. Our objective is to have a robust and flexible manufacturing and supply chain established in good time ahead of the planned US submission of CAM2029 in GEP-NET, subject to a positive result in the SORENTO study.

GEP-NET represents a significant opportunity for CAM2029. Somatostatin receptor ligands (SRL) are the standard first-line treatment, and we estimate that 38,000 patients with metastatic GEP-NET are treated with SRLs in the US alone.1 The pivotal Phase 3 SORENTO study includes 332 patients in twelve countries globally and is the largest randomized study of an SRL in GEP-NET.

A positive outcome on the primary endpoint of progression-free survival could position CAM2029 as a new first-line treatment option.

The target of 194 events (tumor progression or death) required for readout of results is estimated to be reached around the end of the year, reflecting the rate of accrual, and topline results are expected in the first quarter of 2027.

In polycystic liver disease (PLD), we expect new data from the ongoing POSITANO extension study by year-end. The result will inform decisions and planning in the development program in the indication, which will be considered in the context of the SORENTO results.

Early-stage pipeline and partnerships

During the quarter, the clinical trial application was approved for a randomized, placebo-controlled, Phase 2b study with CAM2056, our once-monthly semaglutide in patients with obesity. The first patients were dosed after the period, and the study is progressing to plan. In parallel, we continue to advance the development of a new autoinjector pen for CAM2056.

Also, our collaborations with Lilly on long-acting incretins, recently expanded to amylin receptor agonists, and with Gubra on a long-acting parathyroid hormone analog, advanced as planned.

Changes in the Executive Management Team

Richard Jameson, Chief Commercial Officer, will retire at the end of 2026 after more than ten years with Camurus. As the company’s first commercial hire, Richard has been instrumental in building our operation in Europe, Australia and the MENA region. He remains in his position through year-end to support an orderly transition and will thereafter support Camurus as an advisor.

Starting 1 January, Samantha Nickerson will succeed Richard as SVP International Commercial and join the Executive Management Team. Samantha joined Camurus in 2020 as General Manager of the UK & Ireland affiliate and assumed additional responsibility for the Benelux region in 2023. Under her leadership, the UK has developed into one of Camurus’ larger markets, with expanded patient access.

I would like to thank Richard for his significant contributions to Camurus and welcome Samantha to her new role.

Outlook and long-term growth

Camurus had a strong third quarter with important milestones ahead. Based on performance to date, we now expect full-year revenues and operating result to be in the upper half of the guided ranges of SEK 2.6 to 2.9 billion and SEK 0.9 to 1.2 billion, respectively. In the coming months we will focus on the US regulatory process and launch preparations for CAM2029 (Oclaiz), completion of event accrual in SORENTO and readout of results, the execution of the CAM2056 Phase 2b study, and preparations for the Canadian launch of Oczyesa XR.

Camurus is well positioned for continued growth. Buvidal and Brixadi hold leading positions in long-acting treatment of opioid dependence across Europe, Australia and the US, and the develop-ment is in line with our target of 100,000 patients in treatment with Buvidal by the end of 2027. With Oczyesa approved in the EU, the UK, Australia and Canada, and a US decision ahead, we are building a second commercial platform in acromegaly. A positive outcome in SORENTO could extend CAM2029 into first-line treat-ment of GEP-NET, a substantially larger market opportunity. In addition, CAM2056, and our partnerships with Lilly and Gubra, all based on our FluidCrystal® technology, offer opportunities in some of the largest therapeutic areas in healthcare. We have a strong financial position, with record high profitability and SEK 4.4 billion in cash.

Our commitment remains unchanged: to develop and commercialize innovative long-acting medicines that improve the lives of patients with severe and chronic diseases, with the financial and operational discipline that supports profitable, sustainable growth.

I would like to thank our employees for their dedication and our partners for valuable collaboration. We are entering an important period and are looking forward to a strong finish to the year.

Fredrik Tiberg

President and CEO

* Brixadi® is the US brand name for Camurus’ product Buvidal®
** Oclaiz™ is the proposed US brand name for CAM2029 for the treatment of acromegaly.

References

  1. Camurus estimate based on published US epidemiology and treatment-pattern data.